This page has not been authorized, sponsored, or otherwise approved or endorsed by the companies represented herein. Each of the company logos represented herein are trademarks of Microsoft Corporation; Dow Jones & Company; Nasdaq, Inc.; Forbes Media, LLC; Investor's Business Daily, Inc.; and Morningstar, Inc.
Copyright 2025 Zacks Investment Research | 101 N Wacker Drive, Floor 15, Chicago, IL 60606
At the center of everything we do is a strong commitment to independent research and sharing its profitable discoveries with investors. This dedication to giving investors a trading advantage led to the creation of our proven Zacks Rank stock-rating system. Since 1988 it has more than doubled the S&P 500 with an average gain of +23.64% per year. These returns cover a period from January 1, 1988 through August 4, 2025. Zacks Rank stock-rating system returns are computed monthly based on the beginning of the month and end of the month Zacks Rank stock prices plus any dividends received during that particular month. A simple, equally-weighted average return of all Zacks Rank stocks is calculated to determine the monthly return. The monthly returns are then compounded to arrive at the annual return. Only Zacks Rank stocks included in Zacks hypothetical portfolios at the beginning of each month are included in the return calculations. Zacks Ranks stocks can, and often do, change throughout the month. Certain Zacks Rank stocks for which no month-end price was available, pricing information was not collected, or for certain other reasons have been excluded from these return calculations. Zacks may license the Zacks Mutual Fund rating provided herein to third parties, including but not limited to the issuer.
Visit Performance Disclosure for information about the performance numbers displayed above.
Visit www.zacksdata.com to get our data and content for your mobile app or website.
Real time prices by BATS. Delayed quotes by Sungard.
NYSE and AMEX data is at least 20 minutes delayed. NASDAQ data is at least 15 minutes delayed.
This site is protected by reCAPTCHA and the Google Privacy Policy, DMCA Policy and Terms of Service apply.
View All Zacks #1 Ranked Stocks
Zacks News
Zimmer Biomet (ZBH) Q4 Earnings Meet Estimates, Sales Beat (Revised)
by Zacks Equity Research
Zimmer Biomet (ZBH) rides high on Hip and S.E.T segments in Q4.
Hill-Rom (HRC) Beats Q1 Earnings and Revenues, Margins Up
by Zacks Equity Research
Hill-Rom (HRC) rides on strength in Front Line Care and Surgical Solutions segments in Q1.
Abaxis (ABAX) Beats Earnings and Revenue Estimates in Q3
by Zacks Equity Research
Abaxis (ABAX) Q3 earnings gain on strength in Medical and Veterinary segments.
Accuray (ARAY) Q2 Loss Narrower Than Estimates, Revenues Top
by Zacks Equity Research
Radixact System and major software overhaul drive Accuray (ARAY) in Q2.
Varian Gains Ground on New Applications, Grows in Australia
by Zacks Equity Research
Varian's (VAR) innovative product pipeline will continue to drive growth over the long term.
Varian to Open Facility in Brazil, Global Growth in Focus
by Zacks Equity Research
Varian's (VAR) strong overseas presence is likely to fortify its foothold in the emerging markets. The recent initiative would boost its presence in Latin America.
Accuray's (ARAY) Q1 Loss in Line, Revenues Beat Estimates
by Zacks Equity Research
Accuray (ARAY) rides high on its product and service segments in Q1.
Why Is Accuray (ARAY) Up 9.9% Since the Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings about 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Accuray (ARAY) Grapples With Falling Margin and Product Mix
by Zacks Equity Research
Accuray Inc.'s (ARAY) low product margins and unfavorable product mix will continue to be a drag on the company's performance.
Accuray (ARAY) Q4 Loss Wider Than Expected, Revenues Beat
by Zacks Equity Research
Accuray's (ARAY) new TomoTherapy product platform, also known as Radixact, continues to contribute to the top line. Solid Fiscal 2018 guidance instills investor confidence.
Accuray's Radixact Now Used by Boise Summit Cancer Center
by Zacks Equity Research
Accuray's (ARAY) Radixact system leverages on its flagship TomoTherapy platform. The company's top-line growth is dependent on TomoTherapy system sales.
New Strong Sell Stocks for July 24th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Accuray's Q4 Preliminary Results Fail to Cheer Investors
by Zacks Equity Research
Accuray (ARAY) announced its preliminary results for for the fourth quarter and fiscal 2017. Following the announcement, the company's stock lost over 2% in the last trading session to close at $4.70.
Accuray's Medical Systems to be Acquired by Dubai Hospital
by Zacks Equity Research
Accuray Inc. (ARAY) recently announced that it has signed an agreement with the Neuro Spinal Hospital in Dubai, United Arab Emirates.
New Strong Sell Stocks for July 10th
by Zacks Equity Research
Here are 5 stocks added to the Zacks Rank #5 (Strong Sell) List today:
Why Is Accuray (ARAY) Down 9.8% Since the Last Earnings Report?
by Zacks Equity Research
Accuray (ARAY) reported earnings 30 days ago. What's next for the stock? We take a look at earnings estimates for some clues.
Weakness Seen in Accuray (ARAY) Estimates: Should You Stay Away?
by Zacks Equity Research
Accuray Incorporated (ARAY) has witnessed a significant price decline in the past four weeks, and it has seen negative earnings estimate revisions for the current quarter and the current year.
Accuray (ARAY) Incurs Loss in Q3, Revenues Miss Estimates
by Zacks Equity Research
Accuray Inc.(ARAY) reported a loss of 6 cents per share in the third quarter of fiscal 2017, comparing unfavorably with the Zacks Consensus Estimate of earnings of a penny.
Is Accuray (ARAY) a Great Growth Stock?
by Zacks Equity Research
Accuray (ARAY) looks like an exciting pick for investors as it is poised for strong future growth.
Accuray TomoTherapy System Starts Cancer Treatment in Africa
by Zacks Equity Research
Accuray Inc. (ARAY) recently announced that the Radiotherapy and Medical Oncology Center of Sidi Abdellah, Algeria has finally initiated cancer treatment with the company's flagship TomoTherapy system.
Accuray (ARAY) Incurs Wider Loss in Q2, Misses on Revenue
by Zacks Equity Research
Accuray Inc. (ARAY) reported a loss of 11 cents per share in the second quarter of fiscal 2017, wider than the Zacks Consensus Estimate of a loss of 7 cents.
Why Earnings Season Could Be Great for Accuray (ARAY)
by Zacks Equity Research
Accuray (ARAY) could be an interesting stock for investors ahead of earnings, as it has a positive ESP and a favorable Zacks Rank.
Accuray: Hong Kong Sanatorium to Buy 3 Radixact Systems
by Zacks Equity Research
Accuray Incorporated (ARAY) has signed an agreement with Hong Kong Sanatorium & Hospital per which the latter would purchase three Radixact Systems.
5 MedTech Stocks Poised to Trump Earnings in Q4
by Zacks Equity Research
MedTech's steady earnings trend reflects a strong product cycle and continuing innovation.
4 Hot MedTech Stocks for Q4 Earnings
by Zacks Equity Research
The primary factor that compels us to bet on MedTech, is its fundamental defensive nature.